Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

• Status: Unknown status
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Antidepressive Agents; Bupropion; Citalopram; Duloxetine Hydrochloride; Fluoxetine; Mirtazapine; Nortriptyline; Paroxetine; Sertraline; Trazodone; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

1. 25 < age <85

2. major depressed patients satisfied with the diagnosis criteria depression of DSM-IV

3. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion Criteria:

1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks

2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.